Citation Impact
Citing Papers
Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell–Based Vaccination
2012
Differential Antigen Processing by Dendritic Cell Subsets in Vivo
2007 StandoutScienceNobel
Route of Administration Modulates the Induction of Dendritic Cell Vaccine–Induced Antigen-Specific T Cells in Advanced Melanoma Patients
2011
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
2003 StandoutNobel
The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins
2019 StandoutNobel
Recognition of a Ubiquitous Self Antigen by Prostate Cancer-Infiltrating CD8 + T Lymphocytes
2008 StandoutScienceNobel
Selective delivery of β cell antigen to dendritic cells in vivo leads to deletion and tolerance of autoreactive CD8 + T cells in NOD mice
2008 StandoutNobel
Selective blockade of inhibitory Fcγ receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells
2005 StandoutNobel
Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3 + CD25 + CD4 + regulatory T cells
2005 StandoutNobel
Combinatorial Cancer Immunotherapy
2006
Dendritic cells as therapeutic vaccines against cancer
2005
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Physical Principles of Membrane Shape Regulation by the Glycocalyx
2019 StandoutNobel
DC-based cancer vaccines
2007
A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy
2002
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
Adenovirus Transduction and Culture Conditions Affect the Immunogenicity of Murine Dendritic Cells
2005
Mucin-1 is expressed on dendritic cells, both in vitro and in vivo
2004
Imaging in the era of molecular oncology
2008 StandoutNature
Dendritic Cells
2010
The Human T Cell Response to Melanoma Antigens
2006
Cancer immunotherapy via dendritic cells
2012 Standout
A listing of human tumor antigens recognized by T cells
2001
The use of dendritic cells in cancer immunotherapy
2003 StandoutNobel
Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen
2006
Towards patient‐specific tumor antigen selection for vaccination
2002
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
2014
A listing of human tumor antigens recognized by T cells: March 2004 update
2004
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Dendritic cells: a journey from laboratory to clinic
2003
Cancer immunotherapy: moving beyond current vaccines
2004 Standout
Some interfaces of dendritic cell biology
2003 StandoutNobel
Taming cancer by inducing immunity via dendritic cells
2007
Dendritic cells in cancer immunotherapy
2010
Immunity, Inflammation, and Cancer
2010 Standout
Dendritic cell subsets in health and disease
2007
Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories™
2002
Taking dendritic cells into medicine
2007 StandoutNatureNobel
Cancer vaccines: between the idea and the reality
2003
In vivo antigen delivery by aSalmonella typhimurium type III secretion system for therapeutic cancer vaccines
2006
Cancer immunotherapy comes of age
2011 StandoutNature
The First 1000 Dendritic Cell Vaccinees
2003
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
2015 StandoutNature
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
2012 StandoutNatureNobel
Dendritic cell immunotherapy: mapping the way
2004
Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma
2004
T-cell responses of vaccinated cancer patients
2003
Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates
2011 StandoutNobel
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade
2008 StandoutNobel
Dendritic cells with TGF-β1 differentiate naïve CD4+CD25−T cells into islet-protective Foxp3+regulatory T cells
2007 StandoutNobel
Intensified and protective CD4+ T cell immunity in mice with anti–dendritic cell HIV gag fusion antibody vaccine
2006 StandoutNobel
DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8 + T cells in a spectrum of human MHC I haplotypes
2007 StandoutNobel
The tumor suppressor TSLC1/NECL-2 triggers NK-cell and CD8+ T-cell responses through the cell-surface receptor CRTAM
2005
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells
2012 StandoutNobel
Activation of Natural Killer T Cells by α-Galactosylceramide Rapidly Induces the Full Maturation of Dendritic Cells In Vivo and Thereby Acts as an Adjuvant for Combined CD4 and CD8 T Cell Immunity to a Coadministered Protein
2003 StandoutNobel
Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A
2011 StandoutNobel
Generation of Th1-Polarizing Dendritic Cells Using the TLR7/8 Agonist CL075
2010
Network of dendritic cells within the muscular layer of the mouse intestine
2005 StandoutNobel
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
2008 StandoutNobel
Increase in TNF-α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a)
2005 StandoutNobel
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
2003 StandoutNobel
Effector Function of Human Tumor-Specific CD8 T Cells in Melanoma Lesions: A State of Local Functional Tolerance
2004
Glycolipid α-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice
2006 StandoutNobel
The future of immune checkpoint therapy
2015 StandoutScienceNobel
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome
2007 StandoutNobel
Dendritic Cells Charged with Apoptotic Tumor Cells Induce Long-Lived Protective CD4+ and CD8+ T Cell Immunity against B16 Melanoma
2003 StandoutNobel
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells.
2003
HUMAN T CELL RESPONSES AGAINST MELANOMA
2005
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
2008 StandoutNobel
Immunotherapy: Bewitched, Bothered, and Bewildered No More
2004 StandoutScienceNobel
Dendritic cell targeted HIV gag protein vaccine provides help to a DNA vaccine including mobilization of protective CD8 + T cells
2010 StandoutNobel
Tolerogenic Dendritic Cells
2003 StandoutNobel
Therapeutic cancer vaccines
2015
HIV-1-infected monocyte-derived dendritic cells do not undergo maturation but can elicit IL-10 production and T cell regulation
2004 StandoutNobel
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Rational approaches to human cancer immunotherapy
2003
The microbial mimic poly IC induces durable and protective CD4+T cell immunity together with a dendritic cell targeted vaccine
2008 StandoutNobel
Dendritic Cell Surface Calreticulin Is a Receptor for NY-ESO-1: Direct Interactions between Tumor-Associated Antigen and the Innate Immune System
2006
Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody
2018 StandoutNobel
Works of Erwin Schultz being referenced
Tumor‐specific shared antigenic peptides recognized by human T cells
2002
A MAGE‐3 peptide presented by HLA‐B44 is also recognized by cytolytic T lymphocytes on HLA‐B18
2002
Twelve-year survival and immune correlates in dendritic cell–vaccinated melanoma patients
2017
A MAGE‐3 peptide recognized on HLA‐B35 and HLA‐A1 by cytolytic T lymphocytes
2001
The Production of a New MAGE-3 Peptide Presented to Cytolytic T Lymphocytes by HLA-B40 Requires the Immunoproteasome
2002
Identification of Five MAGE-A1 Epitopes Recognized by Cytolytic T Lymphocytes Obtained by In Vitro Stimulation with Dendritic Cells Transduced with MAGE-A1
1999
Generation of an Optimized Polyvalent Monocyte-Derived Dendritic Cell Vaccine by Transfecting Defined RNAs after Rather Than before Maturation
2005
Functional Analysis of Tumor-Specific Th Cell Responses Detected in Melanoma Patients after Dendritic Cell-Based Immunotherapy
2004
Rapid Induction of Tumor-specific Type 1 T Helper Cells in Metastatic Melanoma Patients by Vaccination with Mature, Cryopreserved, Peptide-loaded Monocyte-derived Dendritic Cells
2002
A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes.
2000